Business · 16/11/20261 min read
Akeso's Gumokimab (IL-17A) Receives NMPA Approval for Active Ankylosing Spondylitis
Summary
HONG KONG, Nov. 16, 2026 — Akeso, Inc. (9926.HK) announced that the National Medical Products Administration (NMPA) of China has approved the supplemental New Drug Application (sNDA) for gumokimab, its self-developed IL-17A monoclonal antibody, for the treatment of active...